St. Louis School of Medicine: Investigational drug for genetic form of ALS improves disease's molecular signs
September 22, 2022
September 22, 2022
ST. LOUIS, Missouri, Sept. 22 (TNSjou) -- The Washington University St. Louis School of Medicine issued the following news release:
* * *
Extended use of tofersen may help stabilize muscle strength, control
* * *
An investigational drug developed to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS) reduced molecular signs of the fatal, paralyzing disease and curbed neurodegeneration -- but at the six-month mark, the drug did n . . .
* * *
Extended use of tofersen may help stabilize muscle strength, control
* * *
An investigational drug developed to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS) reduced molecular signs of the fatal, paralyzing disease and curbed neurodegeneration -- but at the six-month mark, the drug did n . . .